中成药说明书功能表述现状及建议

doi:10.19803/j.1672-8629.20240666

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (2): 193-196.
DOI: 10.19803/j.1672-8629.20240666

中成药说明书功能表述现状及建议

张美微¹, 李可千¹, 姚克宇^2#, 朱彦^2,*

¹长春中医药大学医药信息学院,吉林长春 130117;
²中国中医科学院中医药信息研究所,北京 100700

收稿日期:2024-08-27 出版日期:2025-02-17 发布日期:2025-02-17
通讯作者: ^*朱彦,男,博士,副研究员,中医药信息学。E-mail：zhuyan166@126.com;^#为共同通信作者。
作者简介:张美微,女,硕士,中医药大数据分析与挖掘。
基金资助:
国家自然科学基金资助项目(82174534); 中国中医科学院科技创新工程项目资助(CI2021A05306); 中央级公益性科研院所基本科研业务费专项资金资助(ZZ13-YQ-126); 中央级公益性科研院所基本科研业务费（ZZ160311）

Current Descriptions of Functions in Package Inserts of Chinese Herbal Patent Medicines

ZHANG Meiwei¹, LI Keqian¹, YAO Keyu^2#, ZHU Yan^2,*

¹School of Medical Information, Changchun University of Traditional Chinese Medicine, Changchun Jilin 130117, China;
²Institute of Traditional Chinese Medicine Information; Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China

Received:2024-08-27 Online:2025-02-17 Published:2025-02-17

摘要/Abstract

摘要： 目的梳理中成药说明书功能表述现状,分析并提出相应的建议,为药品上市许可持有人（Marketing Authori-zation Holder, MAH）进行药品研发、说明书撰写提供参考。方法分析国家药品监督管理局网站、《中华人民共和国药典》（2020年版）、国内各级药品标准收集的中成药说明书信息,建立中成药说明书功能表述判定标准与功能术语提取标准,并对提取结果开展人工审核。结果与讨论 大部分中成药说明书【功能主治】项内容的表述与现有既定要求相符,展现出了较高的规范化水平,但在表述规范性、与主治范畴一致性方面仍有待进一步优化。需要通过术语规范化工作的持续深入和积极落实相关主体责任等途径,实现功能规范表述,推动中成药说明书撰写的规范化进程。

关键词: 中成药, 说明书, 功能表述, 规范化, 现状分析

Abstract: Objective To analyze the current descriptions of functions in package inserts of Chinese herbal patent medicines and propose corresponding countermeasures in order to provide a reference for marketing authorization holders (MAHs). Methods The information about package inserts of Chinese herbal patent medicines was retrieved from the official website of the National Medical Products Administration, the Pharmacopoeia of the People's Republic of China (2020 edition), and from standards for pharmaceuticals at each level. A standard for determining descriptions of functions and retrieving terms of functions was established before a manual review and analysis of the results of retrieval were conducted. Results and Conclusion The descriptions of functions and indications in most of the package inserts of Chinese herbal patent medicines meet the current standards. However, the descriptions should be standardized and made more consistent with the targeted indications.

Key words: Chinese Herbal Patent Medicines, Package Inserts, Functional Description, Standardization, Status Analysis

中图分类号:

R994.11

张美微, 李可千, 姚克宇, 朱彦. 中成药说明书功能表述现状及建议[J]. 中国药物警戒, 2025, 22(2): 193-196.

ZHANG Meiwei, LI Keqian, YAO Keyu, ZHU Yan. Current Descriptions of Functions in Package Inserts of Chinese Herbal Patent Medicines[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 193-196.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240666

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I2/193

参考文献

[1] YUE Y, XU H.Study on the Legal Realistic Dilemmas and Countermeasures of the Clinical Application of the Off-label Drug Use[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2023, 40(14): 2003-2009.
[2] XU M, ZHANG Q.Analyze the Problems Existing in the Instruction Manual of Chinese Patent Medicine[J]. Guide of China Medicine(中国医药指南), 2022, 20(14): 101-103, 107.
[3] NMPA. National Medical Products Administration. Notice on Issuing the Detailed Rules for the Standardization of Non Prescription Drug Instructions[EB/OL]. (2006-10-20)[2024-11-08]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20061020010101266.html.
[4] NMPA. Notice on the Writing Requirements and Guiding Principles for the Format and Content of Prescription Drug Instructions for Traditional Chinese Medicine and Natural Medicine[EB/OL]. (2006-06-22)[2024-11-08]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060622010101502.html.
[5] WU L, MENG S.Survey and Analysis on 318 Instructions of Chinese Traditional Patent Medicine Used in Internal Medicine[J]. Chinese Journal of Information on Traditional Chinese Medicine(中国中医药信息杂志), 2019, 26(1): 128-131.
[6] TIAN S, GUO H, MIAO MS.Thinking and Practice on the Perfection of Chinese Patent Medicine Directions[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2018, 33(6): 2225-2229.
[7] WU Y, CHENG JA, WU G, et al.Investigation on the difference of Main and Therapeutic Items of Traditional Chinese Patent Drugs Package Inserts from Different Manufacturers or Dosage Forms with the Same Composition[J]. Journal of Traditional Chinese Medicine Management(中医药管理杂志), 2022, 30(13): 26-28.
[8] MEDICINE NTCFSOTC.National Technical Committee for Standardization of Traditional Chinese Medicine: GB/T16751.3-2023[S]. Beijing: State Administration for Market Regulation, National Standardization Administration, 2023: 236.
[9] DUAN S, ZHANG J.Research on the Current Legal Regulation Status and Strategies of Proprietary Chinese Medicines Instructions[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2024(3): 88-95.
[10] NMPA. Regulations on The Management of Drug Instructions and Labels[EB/OL]. (2006-03-15)[2024-11-08]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html.
[11] YIN Y, ZHANG H, GAO R.Discussion on the Problem and Current Situation of the Use of Chinese Patent Medicine Based on Literature of Prescription Comment and Prescription Analysis[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(4): 364-371.
[12] LU Y.Analysis of Foreign Regulatory Policy for Pediatric Research and Development and Application[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(9): 527-532.
[13] State Administration for Market Regulation. Measures for the Administration of Drug Registration[EB/OL]. (2020-01-22)[2024-11-08]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html.
[14] NMPA. Announcement of the National Medical Products Administration on the Release of the“Regulations on the Supervision and Administration of Drug Quality and Safety Subject Responsibility Implementation by Drug Marketing Authorization Holders”(No. 126 of2022)[EB/OL]. (2022-12-19)[2024-11-08]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20221229195805180.html.
[15] NMPA. Announcement of the National Medical Products Administration on Strengthening the Supervision and Management of Production Commissioned by Drug Marketing Authorization Holders (No. 132 of2023)[EB/OL]. (2023-10-23)[2024-11-08]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20231023160426145.html.
[16] GAN C, CHENG L, YUAN Y, et al.Analysis of the Implementation Status and Countermeasures of Drug Marketing Authorization Holder System in China[J]. Journal of Pharmaceutical Research(药学研究), 2024, 43(5): 449-454.

中成药说明书功能表述现状及建议

Current Descriptions of Functions in Package Inserts of Chinese Herbal Patent Medicines

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李波, 徐柳, 谢雨晴, 王艺颖, 董帅, 廉洁, 李国栋, 曹卉娟. 中成药治疗新型冠状病毒感染安全性和有效性的伞状评价[J]. 中国药物警戒, 2025, 22(2): 155-161.
[2]	王涵, 王存轩, 吕雪海月, 张丽宁, 索于思, 顾知恩, 王萍, 金雪晶. 中成药在恶性肿瘤辅助治疗中预防骨髓抑制发生的网状Meta分析[J]. 中国药物警戒, 2025, 22(2): 169-176.
[3]	朱兰, 邵波, 朱彦, 戴洁, 钟诗琦. 已上市中成药说明书安全信息修订实践与思考[J]. 中国药物警戒, 2025, 22(2): 188-192.
[4]	周坤, 马良, 李肇丰, 曹斌, 顾洪伟, 刘茜. 某市精神卫生中心安神类中成药用药分析[J]. 中国药物警戒, 2025, 22(2): 211-216.
[5]	邵波, 钟露苗, 成雨竹, 邓华, 朱兰. 银黄口服制剂安全性风险分析及思考[J]. 中国药物警戒, 2025, 22(1): 84-87.
[6]	路振凯, 杨顶权, 谢振年, 王连心, 黎元元, 王志飞, 崔鑫, 谢雁鸣. 《外用中成药临床应用药物警戒指南》解读与启示[J]. 中国药物警戒, 2024, 21(9): 1029-1033.
[7]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[8]	邵波, 郭晓昕. 中药药物警戒回顾与思考[J]. 中国药物警戒, 2024, 21(7): 741-745.
[9]	潘知玉, 朱健, 于亚南, 刘骏, 姜燕华, 钱真真, 吴广, 王忠, 武红莉, 荆志伟. 3010例芪蛭通络胶囊的真实世界安全性研究[J]. 中国药物警戒, 2024, 21(6): 660-665.
[10]	刘翠丽, 吴晨, 王涛. 吡拉西坦制剂安全性风险分析及思考[J]. 中国药物警戒, 2024, 21(5): 563-566.
[11]	余馨, 贡磊磊, 姚伟洁, 袁偲偲, 冯欣. 中成药治疗复发性流产的临床研究概况性综述[J]. 中国药物警戒, 2024, 21(4): 361-365.
[12]	刘洁, 张建民, 张晓朦, 刘芳, 宋远, 钟旭丽. 某院中成药说明书的儿科用药风险分析与管理思考[J]. 中国药物警戒, 2024, 21(4): 422-427.
[13]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[14]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[15]	孟康康, 汤韧. 羟苯磺酸钙口服制剂上市后安全性分析[J]. 中国药物警戒, 2024, 21(11): 1288-1292.